An Initial Experience With the Disposable Celsio Cryocatheter System for Diagnostic and Interventional Bronchoscopy (CELSIO)
This clinical trial is intended for patients awaiting an interventional bronchoscopy procedure where the use of a cryocatheter is considered. This type of catheter is already used in clinical practice for the treatment of certain types of bronchial obstructions, including tumors, granulomas, and for foreign bodies extractions. This catheter uses extremely cold temperatures offering unique advantages compared to heat-based technologies. Different types of reusable and single-use cryocatheters are actually available on the market. This type of device requires the use of expensive and bulky consoles operating with heavy gas tanks, resulting in high maintenance costs. A Quebec, Canada based company has developed a cryocatheter that combines procedural efficacy with practical considerations in mind. The Celsio cryocatheter operates without a console and is designed to accommodate the bronchscopist through the different types of cryogenic procedures.
This study aims to generate meaningful, real-world evidence without interfering with standard clinical care. The collected data will serve to characterize the device's performance profile, identify best practices for its use, and provide data for the design of future prospective comparative studies.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Marc Fortin, MD, MSc
- Phone Number: 4747 1-418-656-8711
- Email: marc.fortin@criucpq.ulaval.ca
Study Locations
-
-
Quebec
-
Québec, Quebec, Canada, G1V 4G5
- Institut Universitaire De Cardiologie Et De Pneumologie De Québec
-
Contact:
- Marc Fortin, Md, MSc
- Phone Number: 418-656-8711
- Email: marc.fortin@criucpq.ulaval.ca
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient undergoing a bronchoscopic procedure with planned use of a 1.7mm cryocatheter
Exclusion Criteria:
- Patient undergoing a bronchoscopic procedure with planned use of a different size cryocatheter (eg 1.1 or 2.4mm)
- Current pregnancy or lactation
- Lack of free and informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: undergoing bronchoscopic procedures using the Celsio Cryocatheter Device
Subject with a clinically required bronchoscopic intervention planned with the use of a cryocathter (cryobiopsy or cryo-extraction or cryo-devitalization) will undergo the procedure with the Celso cryocathter device
|
The clinicaly required bronchosopic intervention requiring the use of a cryocatheter will be done with the Disposable Celsio Flexible Cryocatheter System
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Procedural completion rate
Time Frame: From first bronchoscope introduction into the patient (beginning of the procedure) to last bronchoscope removal (end of the procedure)
|
Procedural completion will be defined as the completion of all planned procedure steps involving the study device, without device technical dysfunction
|
From first bronchoscope introduction into the patient (beginning of the procedure) to last bronchoscope removal (end of the procedure)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse events rate
Time Frame: During the procedure until 30 days post-intervention
|
Adverse Events (SAEs) include pneumothorax rand bleeding, and 30-day mortality
|
During the procedure until 30 days post-intervention
|
|
Diagnostic yield
Time Frame: From procedure to end of follow up at 2 years
|
According to the Delphi Consensus Definition of Diagnostic Yield and Recommandations for Patient-centered Study Deisgns of the ATS/ACCP Research Statemen
|
From procedure to end of follow up at 2 years
|
|
Procedural duration
Time Frame: From beginning of the procedure to end of the procedure
|
From first bronchoscope introduction into the patient (beginning of the procedure) to last bronchoscope removal (end of the procedure)
|
From beginning of the procedure to end of the procedure
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2026-4542
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Interstitial Lung Disease (ILD)
-
NCT07628725Not yet recruitingInterstitial Lung Disease (ILD)
-
NCT07315425Not yet recruitingInterstitial Lung Disease (ILD)
-
NCT07500818RecruitingInterstitial Lung Disease (ILD) | Lung Biopsy
-
NCT07570836Not yet recruitingInterstitial Lung Disease (ILD)
-
NCT07411066Not yet recruitingInterstitial Lung Disease (ILD)
-
NCT07305220Not yet recruitingInterstitial Lung Disease (ILD)
-
NCT07441278Not yet recruitingPulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
-
NCT06655090RecruitingInterstitial Lung Disease (ILD)
-
NCT02645968CompletedInterstitial Lung Disease (ILD)
-
NCT06825169Not yet recruiting
Clinical Trials on Disposable Flexible Cryocatheter System
-
NCT05646069Completed
-
NCT06422312WithdrawnBladder Cancer | Bladder Outlet Obstruction | Renal Disease | Renal Stone | Bladder Stone
-
NCT06491524Completed
-
NCT03359148CompletedContaminated Medical or Biological Substances | Environmental-Pollution-Related Condition
-
NCT06052098RecruitingStage IA Lung Cancer
-
NCT06698627Enrolling by invitationStress Urinary Incontinence in Women
-
NCT06868108Enrolling by invitation
-
NCT07225933Active, not recruitingUrolithiasis | Kidney Stone | Kidney Stones
-
NCT05670964TerminatedHemodialysis Catheter Infection | Renal Disease, Chronic